Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Operational Pathways for Biomarker Testing in NSCLC



ReachMD Healthcare Image

How can you address common challenges and incorporate biomarker testing into non-small cell lung cancer care?

  • Sponsored by

  • Overview

    Over the past decade, biomarker testing has become significant in non-small cell lung cancer1,2 (NSCLC) due to the rapidly increasing number of actionable biomarkers.2,3 However, many challenges remain in its implementation, like the long turnaround time and lack of a standardized process for storing test results. To find out some best practices for incorporating biomarker testing into NSCLC care, Dr. Matt Birnholz speaks with Dr. David Braxton, Chief of Service for Molecular Pathology at Hoag Hospital.



    1. Rolfo C, et al. J Thorac Oncol. 2021;16:1647-1662.
    2. Tan AC, et al. J Clin Oncol. 2022;40:611-625.
    3. Pennell NA, et al. Am Soc Clin Oncol Educ Book. 2019;39:531-542.

    ©2023 Amgen Inc. All rights reserved. USA-510-81463 04/23 

Schedule8 Dec 2023